Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/19/2017 05/22/2017 05/23/2017 05/24/2017 05/26/2017 Date
197.8(c) 199.1(c) 201(c) 201.6(c) 205.4(c) Last
583 975 325 371 375 500 376 458 504 156 Volume
+2.06% +0.66% +0.95% +0.30% +1.88% Change
More quotes
Financials ( CHF)
Sales 2017 4 967 M
EBIT 2017 848 M
Net income 2017 534 M
Debt 2017 2 767 M
Yield 2017 1,33%
Sales 2018 5 744 M
EBIT 2018 1 066 M
Net income 2018 751 M
Debt 2018 2 204 M
Yield 2018 1,55%
P/E ratio 2017 26,01
P/E ratio 2018 21,27
EV / Sales2017 3,64x
EV / Sales2018 3,05x
Capitalization 15 296 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates its business through the Pharma&Biotech and Specialty Ingredients segments.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as... 
More about the company
Surperformance© ratings of Lonza Group AG
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP AG
05/26 TRACON PHARMACEUTICALS, INC. (NASDAQ : TCON) Files An 8-K Other Events
05/22 LONZA : Announces Price Increase for Biocides and Film Preservation Products
05/19 LONZA : Zinc Pyrithione Market Research Study for Forecast 2025, Challenges, Dem..
05/16 LONZA : Invests to Develop Exosomes for Next-Generation Life-Science Application..
05/10 Lonza Announces the Successful Results of the Rights Offering
05/10 LONZA : Announces the Successful Results of the Rights Offering
05/02 LONZA GROUP AG : RIGHTS ISSUE: 2 new shares @ 136 CHF for 7 existing shares
04/28 NEW LONZA CONSUMER CARE PROTOTYPE FO : Highlight Polyaldo ® Emulsifiers and Pres..
04/27 LONZA GROUP AG : Dividend payable from reserves or sale of assets
04/25 Lonza Launches Rights Offering
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/22Lonza : Announces Price Increase for Biocides and Film Preservation Products .. 
05/16Lonza : Invests to Develop Exosomes for Next-Generation Life-Science Applicat.. 
05/11Lonza Group Announces The Successful Results Of The Rights Offering  
05/10Lonza Announces the Successful Results of the Rights Offering  
05/02Lonza Selects JAGGAER to Streamline Sourcing  
More tweets
Qtime:64
News from SeekingAlpha
05/08 G1 Therapeutics Proposes Terms For $100 Million IPO
04/27 G1 Therapeutics Seeks $115 Million IPO
03/17 Lonza Tied To Attractive Markets
03/16 Catalent's Price Is A Little Hard To Swallow
02/28 ALEXION : Weighing The Pros And Cons
Advertisement
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | 4-Traders
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 194  CHF
Spread / Average Target -5,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Rolf Soiron Chairman
Marc Funk Chief Operating Officer
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG23.45%15 703
INCYTE CORPORATION38.04%27 518
QUINTILES IMS HOLDINGS..11.37%18 872
CELLTRION, INC.--.--%10 293
SEATTLE GENETICS, INC.25.11%9 358
ALKERMES PLC4.25%8 839
More Results